GB2090837A - Immunoglobulin conjugates - Google Patents

Abstract

There is described an immunoglobulin conjugate comprising an immunoglobulin or immunoglobulin fragment modified by one or more groups of the following formula which are covalently linked to it: <CHEM> The conjugates are useful in the treatment of cancers and are made by reaction of the immunoglobulin or immunoglobulin fragment with desacetylvinblastine acid azide.

Description

1

GB2090837A 1

SPECIFICATION Immunoglobulin conjugates

5 This invention relates to novel immunoglobulin conjugates which are anti-cancer agents.

In the chemotherapeutic treatment of cancer it is sometimes necessary to employ drugs that are limited in their effectiveness by unwanted side effects on the patient and efforts are continually being made to minimise such effects. One such drug is vindesine, a compound of the following formula (I)

10

10

15 12

13'

20

25

30

V V f'

/ / 9' ■

X 1 ,a*A<

V/sV/ \ /lc Q ...

^ I ri 3

•c2h5

10

Xx \<y\r c/h3

V.l t BT CH=

CH,

ji. F-1 !

•OH

3

C-NH,

(I)

15

20

25

30

vindesine is disclosed, for example, in British Patent 1,463,575 which describes its preparation and biological activity.

This invention provides a novel conjugate comprising an immunoglobulin or immunoglobulin 35 fragment modified by one or more groups of the following formula which are covalently linked to it:

35

40 °Y V°

iTT,i

^ \itf N. \ A

f rxor,

13 V /V 1 V\ 18/*1

45 "i; fT"a

•c2h5

50

55

(ii)

3 t t

40

45

50

55

60 The immunoglobulin or fragment is an antibody or a fragment of an antibody with antigen recognising properties. The preferred immunoglobulin material is an antibody or a fragment of an antibody adapted for recognition of antigens on the surface of malignant cells of the type occurring in the human body. However immunoglobulin materials of other kinds are also included within the scope of the invention since they may be of use in treatment of animals and 65 in control and assay experiments.

60

65

2

GB2090837A 2

The novel conjugates are useful in the treatment of cancers. They are potentially more effective and have fewer side effects by virtue, inter alia, of their ability to increase the concentration of the cytotoxic drug at the site of action.

It is also to be understood that the invention includes conjugates for use in an indirect system 5 in which they are used to recognise an antibody specific to the cell surface antigen. 5

Immunoglobulins specific to antigens on the surface of cells to be killed, and techniques for their production from the serum of immunised animals or by culturing hybridomas secreting monoclonal products, are well known. The preferred type of antibody is an immunoglobulin of the IgG class. Some representative immunoglobulins are as follows 10 (i) Ig from goats or sheep immunised with carcinoembryonic antigen 10

(ii) Ig from rabbit anti-acute lymphoblastic leukemia serum

(iii) Ig from various primate antisera raised against acute lymphoblastic leukemia, acute myleoblastic leukemia, chronic lymphoblastic leukemia and chronic granulocytic leukemia

(iv) Ig from goats or sheep immunised with lung carcinoma material

15 (v) monoclonal Ig from mouse hybridomas secreting anti-human colorectal carcinoma anti- 15 bodies

(vi) monoclonal Ig from mouse hybridomas secreting anti-human melanoma antibodies

(vii) monoclonal Ig from mouse hybridomas secreting antibodies reacting with human leukemia cells

20 (viii) monoclonal Ig from mouse hybridomas secreting antibodies reacting with human neurob- 20 lastoma cells

(ix) monoclonal Ig from mouse hybridomas secreting antibodies reacting with human breast cancer antigens

(x) monoclonal Ig from mouse hybridomas secreting antibodies reacting with human ovarian

25 carcinoma cells 25

(xi) monoclonal Ig from mouse hybridomas secreting antibodies reacting with human osteosarcoma cells.

As indicated above, the conjugate can also be made with immunoglobulin fragments, referred to as Fab, Fab', or F(ab')2 or IgM monomer derived from an antibody by, for example,

30 proteolytic enzyme digestion. Such materials and methods of preparation are well known and it 30 may be mentioned that preferred proteolytic enzymes are pepsin and papain.

Vindesine of formula (I) can be bound to the immunoglobulin material via the carbon atom of the carboxyl residue at the 3-position by reaction with the appropriate azide derivative and the invention includes, as a further aspect, a process for preparing an anti-cancer agent which 35 comprises reacting an immunoglobulin or immunoglobulin fragment with an azide compound of 35 the formula (III)

40 'rrY^f' 0208

*3 *J9 a«

/ ^ \i o' \ j Z

VYYr

(III)

l/,*, \<y \/ _ F~1 i „

55 CH3

40

C-O-CH,

45 M' i i fi 45

50 ' I10 I J 50

i v"..A »• ,ch3

55

n.

This process represents a convenient way of linking the drug vindesine to immunoglobulin 60 under mild conditions whilst maintaining the structural integrity of the immunoglobulin. 60

The process is preferably carried out in an aqueous medium and at a temperature of from 5"C to 25°C, for example.at room temperature, and at a pH of 8.5 to 9.5, preferably 9.0, and results in the attachment by covalent linkage of one or more vinca residues at the free amino groups of the immunoglobulin molecule, for example, amino groups derived from lysine 65 residues. The number of residues attached will depend on the concentration of the reactants and 65

GB2090837A

the duration of the reaction but the average number is usually from 1 for example from 2 to 5.

For example in carrying out the reaction, a solution of the azide in a suitable solvent such as dioxan is slowly added dropwise to a buffered solution of immunoglobulin in for example 0.34 M borate buffer at pH 9. The conjugate is isolated by gel filtration and stored in saturated 5 ammonium sulphate solution being readily brought back into solution by dialysis with borate 5

buffer, or alternatively it can be stored in a refrigerator at 4°C or frozen at for example — 20°C.

The azide reactant of formula (III) can be readily prepared from vinblastine, vinblastine sulphate or desacetylvinblastine by preferential hydrazinolysis of the C3-ester followed by diazotisation as for example described in J.Med.Chem., 1978, Vol. 21, No. 1 pages 88 to 96, 10 and in British Patent 1,463,575 referred to above. Hydrazinolysis of vinblastine at moderate 10 temperatures in methanol solution proceeds yielding predominantly the monohydrazide and reaction of this product at temperatures of 0°C to 10°C with hydrochloric acid and sodium nitrite in a suitable aqueous solvent, yields the desired azide of formula (III) (desacetylvinblastine acid azide).

15 Alternatively the azide of formula (III) can be prepared at a temperature of below 5°C as 15

described above, and, without isolating the azide, the pH is adjusted to 9 and a water miscible solvent, such as for example dioxan, added. The immunoglobulin in borate buffer pH9 is then added and the reaction mixture allowed to rise to room temperature. Excess azide is destroyed with dilute ammonia and the conjugate purified by gel filtration.

20 Evaluation of the conjugate can be carried out using well known techniques such as affinity 20 chromotography. The efficacy of the conjugate can be estimated by counting the number of viable cells after treatment of a suspension of tumour cells with the conjugate, or from measurements of the uptake of tritiated uridine. Protein and drug concentrations are determined by measuring optical densities of conjugate solutions at two wavelengths, for example 270 and 25 280 nm, and relating the values obtained to those for the free drug and unconjugated 25

immunoglobulin at the same two wavelengths.

The novel conjugates of the invention are useful in the treatment of cancers and as such are preferably prepared for use in formulations suitable for injection. Thus the invention includes a pharmaceutical formulation, for example an injectable preparation, comprising a conjugate of the 30 invention together with a pharmaceutically-acceptable carrier or diluent such as are well known 30 in the art. It is preferably in unit dosage form each dosage containing for example from 0.01 to 2 mg of the active ingredient (in terms of the vindesine moiety).

The novel conjugates are effective over a wide dosage range and for example for the treatment of adult humans dosages per week will normally fall within the range of 1 to 10 35 mg/kg (vindesine moiety) more usually in the range of from 3 to 9 mg/kg. However it will be 35 understood that the amount of compound actually administered will be determined by a physician in the light of the relevant circumstances, including the condition to be treated and the chosen route of administration.

The invention is illustrated by the following Examples 40 40

EXAMPLE 1

Preparation of vindesine-sheep-anti-carcinoembryonic antigen conjugate

Desacetyl vinblastine acid hydrazide (6 mg) was dissolved in IN HCL (340 jul) and the solution cooled to 4°C. Sixty microlitres of a 10 mg/ml aqueous solution of sodium nitrite were added 45 and the reaction stirred at 4°C. After 5 minutes, IN NaOH (300 jul) and dioxan (120 ju.l) were 45 added with vigourous stirring, following by 280 /il of a 21.3 mg/ml solution of sheep-anti-CEA in 0.34 M borate buffer pH 8.6. The mixture was stirred at room temperature for 2 hours maintaining pH 9 using N/10 NaOH. Excess azide was destroyed by adding IN NH4 0H(60 jul) and stirring for a further hour. The product was isolated by gel filtration on a 1 X 25.5 cm (20 50 ml) column of Bio-Gel®P-6 equilibrated with phosphate buffered saline. The excluded peak was 50 collected (2.66 ml), and assayed for protein content by the Lowry method and for vindesine by difference spectroscopy. The conjugate so prepared contained 4.6 moles vindesine per mole of ig-

55 EXAMPLE 2 55

Preparation of vindesine-mouse-monoclonal anti-carcinoembryonic antigen conjugate.

Desacetylvinblastine acid hydrazide (10 mg) was dissolved in 1 N HCI (0.56 ml) and the solution cooled to 4"C. One hundred microlitres of a 10 mg/ml solution of sodium nitrite were added and the reaction stirred at 4°C. After 5 minutes, 1 N NaOH (0.5 ml) and dioxan (0.2 ml) 60 were added with vigorous stirring, followed by 0.5 ml of a 15.6 mg/ml solution of mouse 60

monoclonal anti-CEA in 0.34 N borate buffer pH 8.6. The mixture was stirred at room temperature for 2 hours maintaining pH 9 using N/10 NaOH. Excess azide was destroyed by adding IN NH40H (0.1 ml) and stirring for a further hour. The product was isolated by gel filtration on a 1 X 27 cm (21 ml) column of Bio- Gel®P-6 equilibrated with phosphate buffered 65 saline. The excluded peak was collected (4.07 ml) and assayed for protein and vindesine by 65

4

GB2090837A 4

spectroscopy at 270 nm and 280 nm. The conjugate so prepared contained 2.1 moles vindesine per mole of Ig.

EXAMPLE 3

5 Preparation of vindesine-rabbit anti-mouse Ig conjugate. 5

Desacetylvinblastine acid hydrazide (12 mg) was dissolved in 1 N HCI (0.67 ml) and the solution cooled to 4°C. One hundred and twenty microlitres of a 10 mg/ml solution of sodium nitrite were added and the reaction sirred at 4"C. After 5 minutes, 1 N NaOH (0.6 ml) and dioxan (0.24 ml) were added with vigorous stirring, followed by 1.0 ml of an 11.7 mg/ml 10 solution of rabbit anti-mouse Ig in 0.34 M borate buffer pH 8.6. The mixture was stirred at 10 room temperature for 2 hours maintaining pH 9 using N/10 NaOH. Excess azide was destroyed by adding 1 N NH4 OH (0.12 ml) and stirring for a further hour. The product was isolated by gel filtration on a 1.5 X 26 cm (46 ml) column of Bio-Gel®P-6 equilibrated with phosphate buffered saline. The excluded peak was collected (6.22 ml) and assayed for protein and 15 vindesine by spectroscopy at 270 nm and 280 nm. The conjugate so prepared contained 3.2 15 moles vindesine per mole of Ig.

EXAMPLE 4

A preparation of cells growing in culture was dispensed into microtitre culture trays at a level 20 of 104 cells per well. After allowing the cells 24 hours for establishment, replicate wells were 20 treated with a range of concentrations of a conjugate or a control preparation. After six days in culture, the number of cells present in the wells was assessed by direct counting, using an image analyser linked to an inverted microscope.

In one example, a human colon adenocarcinoma cell line was treated with vindesine linked to 25 a monoclonal anti-carcinoembryonic antigen antibody in a molar ratio of 2.1 moles vindesine per 25 mole of Ig (this was the conjugate of Example 2) and the cytostatic effect measured by cell counts, as follows:

Conjugated drug concentration Number of cells/well %of

30 (vindesine, jug/ml) after six days control 30

(mean ± standard deviation) 4 replicates

0 16.3 ± 4.8 X 104 100

0.08 13.8 ± 2.5 X 104 84.6

35 0.40 12.6 ± 1.9 X 104 7 7.4 35

2.00 10.8 ± 3.9 X 104 66.7

10.00 1.9 ± 0.6 X 104 11.9

Claims (6)

1. 40 1. A conjugate comprising an immunoglobulin or immunoglobulin fragment modified by one 40 or more groups of the following formula which are covalently linked to it:

   5

   .OH

   45 , 7 j Y V

   1X V V 4-12,/N£jy \/

   V /X18/ V8/

   i

   J (ID

   ! . *y\

   r-V

   I« f

   \ry ^

   its FH. 1

   45

   13'v 16/\ 1V

   50 > rT""3 50

   55 i T7o T 7n 55

   60 IH3 I 60

   t
2. 2. A conjugate according to claim 1 utilising an IgG immunoglobulin.

   65
3. 3. A conjugate according to either of claims 1 and 2 in which the immunoglobulin or 65

   5

   GB2090837A 5

   immunoglobulin fragment is modified by an average of from 2 to 5 groups of formula (II).
4. 4. A process for preparing a conjugate according to claim 1 which comprises reacting an immunoglobulin or immunoglobulin fragment with an azide compound of the formula

   10

   15

   20

   25

   Y".

   f FTR' <

   13 /V "A /

   Y Vr""*

   •C2H5

   (III)

   CH.

   jjfa W c/003

   PH, Loh

   CH-
5. 5. A pharmaceutical formulation comprising a conjugate according to any of claims 1 to 3 together with a pharmaceutically-acceptable carrier or diluent therefor.
6. 6. A conjugate according to claim 1 substantially as described in any of Examples 1 to 3.

   10

   15

   20

   25

   Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd.—1982.

   Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.